Results 11 to 20 of about 92,352 (267)
CMAJChagas disease persists as a global public health problem due to the high morbidity and mortality burden. Despite the possibility of a cure and advances in transmission control, epidemiological transformations, such as urbanisation and globalisation, and the emerging importance of oral and vertical transmission mean that Chagas disease should be ...
Billick MJ, Silverberg SL.
europepmc +3 more sources
Pediatrics In Review, 2016 Approximately 8 million people worldwide are infected by the protozoan parasite Trypanosoma cruzi, the causative agent of Chagas disease. After a latent period that can last years or decades, 10% to 30% of infected people develop serious complications, such as cardiomyopathy or gastrointestinal dysfunction.
Tustin, Aaron W., Bowman, Natalie M.
openaire +2 more sources
Clinical Microbiology Reviews, 1992 Chagas' disease, caused by Trypanosoma cruzi, is an important cause of morbidity in many countries in Latin America. The important modes of transmission are by the bite of the reduviid bug and blood transfusion. The organism exists in three morphological forms: trypomastigotes, amastigotes, and epimastigotes.
H B, Tanowitz +5 more
openaire +2 more sources
Novel cruzain inhibitors for the treatment of Chagas' disease. [PDF]
, 2012 The protozoan parasite Trypanosoma cruzi, the etiological agent of Chagas' disease, affects millions of individuals and continues to be an important global health concern.
Arkin, Michelle R +6 more
core +1 more source
Mortality among blood donors seropositive and seronegative for Chagas disease (1996-2000) in São Paulo, Brazil: A death certificate linkage study. [PDF]
PLoS Neglected Tropical Diseases, 2017 Individuals in the indeterminate phase of Chagas disease are considered to have mortality rates similar to those of the overall population. This study compares mortality rates among blood donors seropositive for Chagas disease and negative controls in ...
Ligia Capuani +7 more
doaj +1 more source
Longitudinal study of patients with chronic Chagas cardiomyopathy in Brazil (SaMi-Trop project): a cohort profile. [PDF]
, 2016 PurposeWe have established a prospective cohort of 1959 patients with chronic Chagas cardiomyopathy to evaluate if a clinical prediction rule based on ECG, brain natriuretic peptide (BNP) levels, and other biomarkers can be useful in clinical practice ...
Bierrenbach, Ana Luiza +10 more
core +3 more sources
Postgraduate Medical Journal, 2006 Abstract Chagas disease is the clinical condition triggered by infection with the protozoan Trypanosoma cruzi. The infection is transmitted by triatomine insects while blood feeding on a human host. Field studies predict that one third of an estimated 18 million T cruzi-infected humans in Latin America will die of Chagas disease.
A R L, Teixeira +4 more
openaire +2 more sources
A protocol update for the Selenium Treatment and Chagasic Cardiomyopathy (STCC) trial
Trials, 2018 Several studies evaluating clinical forms of chronic Chagas disease show that about one-third of patients present cardiac involvement. Heart failure, sudden death and cardioembolic stroke are the main mechanisms of death in Chagas heart disease.
Marcelo Teixeira Holanda +24 more
doaj +1 more source
Different serological cross-reactivity of Trypanosoma rangeli forms in Trypanosoma cruzi-infected patients sera [PDF]
, 2008 Background American Trypanosomiasis or Chagas disease is caused by Trypanosoma cruzi which currently infects approximately 16 million people in the Americas causing high morbidity and mortality.
de Moraes, Milene H. +7 more
core +3 more sources
Frontiers in Medicine, 2023 Diagnosis of Trypanosoma cruzi (T. cruzi) infection in the chronic phase of Chagas disease (CD) is performed by serologic testing. Conventional tests are currently used with very good results but require time, laboratory infrastructure, and expertise ...
Jacqueline Araújo Domingos Iturra +11 more
doaj +1 more source